PT  - JOURNAL ARTICLE
AU  - Geoffrey M. Currie
AU  - Dale L. Bailey
TI  - A Technical Overview of Technegas as a Lung Ventilation Agent
AID  - 10.2967/jnmt.121.262887
DP  - 2021 Dec 01
TA  - Journal of Nuclear Medicine Technology
PG  - 313--319
VI  - 49
IP  - 4
4099  - http://tech.snmjournals.org/content/49/4/313.short
4100  - http://tech.snmjournals.org/content/49/4/313.full
SO  - J. Nucl. Med. Technol.2021 Dec 01; 49
AB  - Technegas is a carbon-based nanoparticle developed in Australia in 1984 and has been in widespread clinical use, including SPECT imaging, since 1986. Although 81mKr offers the ideal ventilation properties of a true gas, Technegas is considered preferred in more than 60 countries for ventilation imaging yet has limited adoption in the United States. In March 2020, a new U.S. Food and Drug Administration application was lodged for Technegas, and the impending approval warrants a detailed discussion of the technical aspects of the technology for those for whom it is new. Technegas is a simple yet versatile system for producing high-quality 99mTc-based ventilation studies. The design affords safety to patients and staff, including consideration of radiation and biologic risks. Technegas is the gold standard for the ventilation portion of SPECT-based ventilation–perfusion studies in pulmonary embolism and several respiratory pathologies. When approved by the U.S. Food and Drug Administration, Technegas will extend advantages to workflow, safety, and study quality for departments that adopt the technology.